MediciNova, Inc. — Q3 2021 Form 10-Q Summary
Business context and reporting period
MediciNova is a development-stage biopharmaceutical company focused on therapeutics for serious diseases with unmet medical needs. Its principal programs include MN-166 (ibudilast) for neurological and other disorders, MN-001 (tipelukast) for fibrotic diseases, MN-221 (bedoradrine) for acute asthma exacerbation, and MN-029 (denibulin) for solid tumors. The filing covers the three and nine months ended September 30, 2021. The financial statements are unaudited.
Financial performance and liquidity
| Metric | Q3 2021 | Q3 2020 | 9M 2021 | 9M 2020 |
|---|---|---|---|---|
| Revenue | $37,500 | $0 | $4.04 million | $0 |
| Operating expenses | $3.64 million | $3.73 million | $12.15 million | $11.16 million |
| Operating loss | $3.60 million | $3.73 million | $8.11 million | $11.16 million |
| Net loss | $3.58 million | $3.70 million | $8.05 million | $10.87 million |
| Net loss per share | $0.07 | $0.08 | $0.17 | $0.25 |
| Net cash used in operating activities | Not provided for quarter | Not provided for quarter | $5.74 million | $8.88 million |
Q3 operating expenses declined modestly year over year. Research, development and patent expense was $2.09 million, compared with $2.24 million, while general and administrative expense increased to $1.55 million from $1.49 million. The company reported no meaningful product revenue; Q3 revenue consisted of $37,500, while nine-month revenue primarily reflected $4.0 million of milestone payments under the Genzyme Agreement.
Cash and cash equivalents were $75.0 million at September 30, 2021, compared with $60.0 million at December 31, 2020. Working capital was approximately $72.0 million. Management stated that available working capital was expected to fund operations at least through the end of 2022, although it could not assure that funding would support all planned research and development programs.
Financing activities provided $20.74 million during the first nine months, primarily from a January 2021 private placement of 3,656,307 shares that generated approximately $19.9 million of net proceeds, plus proceeds from option exercises. The company had no debt reported in the filing. Total liabilities were $5.14 million, including $888,398 of operating lease liabilities and $1.69 million of current deferred revenue.
Material changes versus the prior comparable period
- Nine-month revenue increased by $4.0 million from zero because two Genzyme-related clinical development milestones were achieved.
- Nine-month net loss improved by $2.8 million, primarily because of the milestone revenue and lower overall operating cash usage.
- Nine-month research, development and patent expense increased by $1.1 million to $6.8 million, mainly because of higher clinical trial costs for the MN-166 ALS program.
- Nine-month general and administrative expense decreased by $0.1 million to $5.4 million, primarily because of lower performance-based stock compensation.
- Cash increased by $15.0 million during the first nine months, principally due to the private placement proceeds exceeding operating and investing cash outflows.
- Shares outstanding increased from 45.0 million at December 31, 2020 to 49.0 million at September 30, 2021, reflecting the private placement, option exercises and employee stock purchases.
Guidance, outlook, commentary, risks and unusual items
MediciNova expects to continue incurring substantial net losses as it advances its development programs. Management expected research and development costs to increase through the remainder of 2021 as programs progress and planned to pursue strategic alliances and pharmaceutical partnerships to support development and commercialization.
The company continued enrolling patients and conducting clinical-trial activities despite COVID-19-related disruptions. Management assessed that COVID-19 was not expected to have a material negative effect on development plans, long-term timelines or liquidity, while noting that the situation remained subject to change.
The company and Kissei were working to terminate the MN-221 collaboration and cancel the remaining study. In October 2021, after the reporting date, MediciNova refunded $1.3 million of the Kissei prepayment and expected to finalize the termination agreement by December 31, 2021. The balance sheet included $1.69 million of current deferred revenue at September 30, 2021.
Key risks include dependence on MN-166 and MN-001, clinical-trial delays or failures, regulatory approval risk, the need for additional capital, reliance on third-party manufacturers and clinical research providers, intellectual-property disputes, competition, reimbursement and market-acceptance risk, COVID-19 effects, and the potential loss of licensed rights. The filing reported no material legal proceedings and no material changes to previously disclosed risk factors.
Stock-based compensation was $2.47 million for the first nine months of 2021. The company had 8.10 million stock options outstanding at September 30, 2021, and 1.1 million of unamortized compensation cost expected to be recognized over approximately 0.40 years.
Important facts for investors to verify
- Whether the Genzyme milestone revenue is recurring or represents a one-time benefit.
- The final terms and accounting effects of the Kissei collaboration termination and the $1.3 million refund.
- Clinical-trial enrollment, milestones, safety and efficacy data for MN-166 and MN-001 programs.
- Whether the stated cash runway through the end of 2022 remains adequate as development spending increases.
- Potential future equity issuance, dilution and availability under the $75.0 million ATM facility.
- The extent to which COVID-19, regulatory decisions, trial delays or third-party dependencies could affect the development timeline and liquidity.